Physician profile
Ashley Callaway
NPI 1346956984
$5,240.43
in general payments reported to CMS, 2019-2025
22 companies · $1,633 in 2025
The $1,633 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,498 · 2024: $1,110 · 2025: $1,633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,060 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,060.46 |
| Education | $179.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,487.55 | 2023-2025 | |
| Amgen INC. | $1,017.85 | 2023-2025 | Enbrel, Otezla, Evenity |
| Janssen Biotech, INC. | $744.25 | 2023-2025 | Tremfya, Simponi Aria |
| Lilly USA, LLC | $380.30 | 2023-2025 | Taltz, Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $296.06 | 2023-2025 | Saphnelo, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $244.00 | 2023-2025 | Trelegy Ellipta, Benlysta |
| Novartis Pharmaceuticals Corporation | $182.11 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.87 | 2023-2025 | Ofev, Cyltezo |
| Pfizer INC. | $103.96 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $99.50 | 2024-2025 | Acthar |
| Novo Nordisk INC | $89.12 | 2023 | Wegovy, Rybelsus, Ozempic |
| Aurinia Pharma U.S., INC. | $78.66 | 2023-2025 | Lupkynis |
| Exact Sciences Corporation | $70.24 | 2023-2024 | Cologuard Collection Kit |
| Fresenius Kabi USA, LLC | $55.88 | 2023 | Idacio |
| Madrigal Pharmaceuticals | $42.81 | 2024 | Resmetirom |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $41.48 | 2023-2025 | Strensiq |
| Genzyme Corporation | $35.76 | 2023 | |
| Sandoz INC. | $28.96 | 2023 | Hyrimoz |
| Sumitomo Pharma America, INC. | $27.74 | 2025 | Gemtesa |
| Ucb, INC. | $27.18 | 2025 | Bimzelx |
| Kyowa Kirin, INC. | $19.32 | 2025 | |
| Organon LLC | $18.83 | 2023 | Hadlima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Callaway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.